Shanghai Bosaimi Biotechnology

Shanghai Bosaimi Biotechnology is a China-based biopharmaceutical company specializing in the discovery and development of innovative small molecule drugs, with a primary focus on targeted protein degradation (TPD). The company leverages its proprietary platform to develop molecular glues and PROTACs aimed at addressing previously undruggable targets in oncology and immunology. Founded in 2020 by experienced industry leaders, Bosaimi has quickly attracted significant investment from prominent venture capital firms like Sequoia China and GL Ventures. The company is headquartered in the Zhangjiang Hi-Tech Park in Shanghai, where it conducts its core research and development activities. Bosaimi aims to translate cutting-edge science into transformative therapies for patients with high unmet medical needs globally.